Royal Philips has signed a memorandum of understanding with Ypsomed, a self-medication systems maker, to co-develop and deploy new digital services for the monitoring of medication adherence.
The new SmartServices will be backed by Philips’ Cloud-based HealthSuite digital platform, which offers tools and services for easy integration, management and end-to-end security.
SmartServices will comprise a set of digital services to address device-related challenges and support self-medication for patients with chronic diseases such as diabetes and rheumatoid arthritis.
Ypsomed Delivery Systems senior vice-president Ulrike Bauer said: “Our partnership with Philips aims at embedding smart devices in a digital health ecosystem that simplifies access to therapy-relevant medication adherence data.
“This will allow our pharmaceutical customers to focus on building therapy-specific digital solutions for patients, caregivers and physicians.”
Ypsomed supplies injections pens, autoinjectors and infusion systems to pharmaceutical and biotech companies under mylife Diabetescare and YDS Ypsomed Delivery Systems brands.
The deal will facilitate the integration of Ypsomed’s smart medical devices into Philips HealthSuite digital platform thereby improving therapy-specific care pathways.
Royal Philips HealthSuite digital platform business leader Dale Wiggins said: “Integrating Ypsomed’s smart devices and data into the Philips HealthSuite ecosystem means pharma companies will be able to develop solutions that leverage HealthSuite’s secure, Cloud-based services.
“It will shorten time-to-market, enable them to scale-up solutions in a secure HIPAA-compliant way, and allow them to integrate data from Ypsomed devices with other data sources to support many different value-added use cases.”
To further the deal, the companies plan to enter into definitive agreements over the coming months.